Neuromyelitis Optica Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Neuromyelitis Optica clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting
Phase 3

A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum DisorderNMOSD
Hoffmann-La Roche8 enrolled12 locationsNCT05199688
Recruiting
Phase 4

Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study

Neuromyelitis Optica Spectrum Disorder Attack
Chinese PLA General Hospital200 enrolled1 locationNCT07410039
Recruiting
Phase 4

Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorders (NMOSD)
Tianjin Medical University General Hospital198 enrolled1 locationNCT07420296
Recruiting

Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies

Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc.122 enrolled33 locationsNCT05966467
Recruiting
Phase 1Phase 2

Ofatumumab in AQP4-IgG Seropositive NMOSD

Neuromyelitis Optica Spectrum Disorder
Tang-Du Hospital5 enrolled1 locationNCT05504694
Recruiting

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Pregnancy RelatedNeuromyelitis Optica Spectrum Disorder
Amgen60 enrolled1 locationNCT05909761
Recruiting
Phase 1

The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders

Neuromyelitis Optica Spectrum Disorders
Tongji Hospital69 enrolled1 locationNCT06620809
Recruiting

French Registry for Monitoring Pregnancies for Multiple Sclerosis

Sclerosis, MultipleNeuromyelitis Optica Spectrum DisorderMyelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders+1 more
Hospices Civils de Lyon1,500 enrolled48 locationsNCT03900221
Recruiting
Early Phase 1

Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases

Myasthenia GravisAutoimmune EncephalitisMultiple Sclerosis+2 more
Tianjin Huanhu Hospital12 enrolled1 locationNCT06939166
Recruiting
Phase 2

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder
Amgen15 enrolled19 locationsNCT05549258
Recruiting
Phase 2Phase 3

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.12 enrolled21 locationsNCT05346354
Recruiting

Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging

Multiple SclerosisAlzheimer DiseaseParkinson Disease+2 more
Assistance Publique Hopitaux De Marseille700 enrolled1 locationNCT07202494
Recruiting
Phase 2

Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder Attack
Tianjin Medical University General Hospital110 enrolled1 locationNCT07184840
Recruiting

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica
University of Texas Southwestern Medical Center35 enrolled1 locationNCT06398158
Recruiting
Phase 1

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Myasthenia GravisSystemic Lupus Erythematosus (SLE)Multiple Sclerosis (MS)+3 more
RenJi Hospital30 enrolled1 locationNCT06249438
Recruiting
Phase 1

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Myasthenia GravisMultiple Sclerosis (MS)Neuromyelitis Optica Spectrum Disease (NMOSD)+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology37 enrolled3 locationsNCT06869278
Recruiting
Not Applicable

Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorders
Third Affiliated Hospital, Sun Yat-Sen University144 enrolled1 locationNCT06763848
Recruiting
Not Applicable

Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD

Neuromyelitis Optica Spectrum Disorder (NMOSD)
Icahn School of Medicine at Mount Sinai20 enrolled1 locationNCT06780709
Recruiting
Not Applicable

Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

Neuromyelitis Optica
Ad scientiam103 enrolled22 locationsNCT05566769
Recruiting
Not Applicable

Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.

Multiple SclerosisNeuromyelitis Optica Spectrum DisordersMOGAD
Fondazione Policlinico Universitario Agostino Gemelli IRCCS50 enrolled1 locationNCT06865274